Adamik, Juraj
Munson, Paul V.
Maurer, Deena M.
Hartmann, Felix J. http://orcid.org/0000-0002-4174-2276
Bendall, Sean C. http://orcid.org/0000-0003-1341-2453
Argüello, Rafael J. http://orcid.org/0000-0001-9785-3883
Butterfield, Lisa H. http://orcid.org/0000-0002-3439-9844
Funding for this research was provided by:
Parker Institute for Cancer Immunotherapy
Article History
Received: 30 March 2023
Accepted: 24 October 2023
First Online: 8 November 2023
Competing interests
: J.A., P.V.M., D.M.M., F.J.H., S.C.B.: declare no competing interests. L.H.B. declares the following unrelated competing interests: Calidi Scientific and Medical Advisory Board, April 6, 2017–2023; KaliVir, Scientific Advisory Board, 2018–2023; Torque Therapeutics, Scientific Advisory Board, 2018–2020; Khloris, Scientific Advisory Board, 2019–2023; Pyxis, Scientific Advisory Board, 2019–2023; CytomX, Scientific Advisory Board, 2019–2023; DCprime, Scientific Advisory Board meeting, 2020; RAPT, Scientific Advisory Board, 2020–2023; Takeda, Scientific Advisor, 2020–2023; EnaraBio scientific advisor, Feb. 2021. R.J.A. declares no competing interests. There are restrictions to the commercial use of SCENITH due to a pending patent application (PCT/EP2020/WO2020212362A1).